CNS research seeks to advance treatment for central nervous system disorders through the discovery and quantitation of biomarkers, mechanisms, and drug targets. Our broad range of CNS products meets all the needs of in vitro, in situ, and in vivo central nervous system research.
We offer biomarker detection kits with AlphaLISA? and LANCE? TR-FRET technology, cellular and in vivo imaging systems, and tissue pathology solutions to assess mechanisms of CNS disease in biochemical, cellular, tissue, and animal models. We also provide target-specific radiochemicals, radioligands, and receptor-transfected cell lines and cell membranes.
Applications for our CNS products include:
Our CNS products are also well suited for CNS research in neurodegenerative diseases such as Alzheimer’s, Parkinson’s, and Huntington’s. Gain precise insight on disease biomarkers like phospho-tau, Ab42/Ab40, vimentin, and frataxin, as well as relevant receptors such as dopamine DA1R/DA2R.
3 Business Insights
This paper explores the numerous challenges materials scientists and engineers face, from the time it takes to bring new materials to market to the difficulties delivering suitable formulations and testing against specified criteria, and how those can be resolved.
Analyzing transport of biliary metabolites is essential to predict pharmacokinetics and hepatotoxicity during drug development. A functional impairment of hepatobilary transporters, such as bile salt export pump (BSEP) and multidrug resistance-associated protein 2 (MRP-2), is strongly associated with an increased risk of cholestatic liver injury. Here, we describe a 3D high-content screening assay to study hepatobiliary transporter function in InSphero human liver microtissues. Confocal imaging and automated image analysis were used to quantify BSEP and MRP-2-mediated efflux of fluorescent substrates into bile canaliculi.